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Abstract
Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is a heterogeneous disorder
from both clinical and pathogenic viewpoints. Executive function deficits are considered among the
most important pathogenic pathways leading to ADHD and may index part of the heterogeneity in
this disorder.
Methods: To investigate the relationship between the dopamine transporter gene (SLC6A3) 3'-
UTR VNTR genotypes and executive function in children with ADHD, 196 children diagnosed with
ADHD were sequentially recruited, genotyped, and tested using a battery of three
neuropsychological tests aimed at assessing the different aspects of executive functioning.
Results: Taking into account a correction for multiple comparisons, the main finding of this study
is a significant genotype effect on performances on the Tower of London (F = 6.902, p = 0.009) and
on the Wechsler Intelligence Scale for Children, Third Edition (WISC-III) Freedom From
Distractibility Index (F = 7.125, p = 0.008), as well as strong trends on Self Ordered Pointing Task
error scores (F = 4,996 p = 0.026) and WISC-III Digit Span performance (F = 6.28, p = 0.023).
Children with the 9/10 genotype exhibited, on average, a poorer performance on all four measures
compared to children with the 10/10 genotype. No effect of genotype on Wisconsin Card Sorting
Test measures of performance was detected.
Conclusion:  Results are compatible with the view that SLC6A3  genotype may modulate
components of executive function performance in children with ADHD.
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Background
ADHD is a heterogeneous disorder characterized by age-
inappropriate inattention, motor activity, and/or impulse
control. Its high prevalence in school-aged children (8 to
12%) [1] in combination with its significant negative
impact on school and social adjustment as well as family
wellbeing make it one of the most important public
health problems in the child population. Multiple risk
factors interact to increase liability to ADHD [2]. While
environmental risk factors such as pregnancy complica-
tions [3], family dysfunction [4] and drug abuse during
pregnancy [5] have all been implicated in the etiology of
ADHD, there is overwhelming evidence from twin studies
that genes also contribute to the development of ADHD
[2,6,7].
There has been a strong focus on the dopamine trans-
porter in ADHD as psychostimulants, the first line medi-
cation for ADHD, have been shown to block this
transporter as part of their mechanism of action [8]. Fur-
ther, single photon emission computed tomography stud-
ies show high rates of striatal dopamine transporter
activity in drug naive adults with ADHD [9-11]. In keep-
ing with this, a pooled odds ratio (OR) for ADHD from
family studies for the dopamine transporter (DAT1) gene
10 repeat allele was found to be significant [6] and other
meta-analyses have invariably shown positive ORs for this
allele [12-16], although not necessarily significant ones.
While the above-mentioned genetic studies have exam-
ined allelic associations between specific polymorphisms
and ADHD, genotypic approaches have also yielded sup-
port for DAT1 involvement. For instance, Loo et al. have
reported that in patients with ADHD, there is an associa-
tion between 10/10 DAT1 genotype and increased errors
on a vigilance task when compared to a compound group
composed of children having the 9/9 or 9/10 genotypes
[17]. Along similar lines, children with ADHD and carri-
ers of both the 10/10 DAT1 genotype as well as a 7-repeat
DRD4 allele have been reported as having a lower IQ than
a combined group of carriers of other genotypes [18]. Fur-
ther, poor response to methylphenidate was associated, in
ADHD children, with DAT1 10-repeat allele homozygos-
ity in both prospective and naturalistic studies [19-21].
Due to the relatively small frequency of the 9/9 genotype
in the general population and to the consequently small
sample sizes generally acquired for this genotype, 10/10
genotype groups are usually compared to a combined
group of subjects with the 9/9 and 9/10 genotypes (as well
as other very rare genotypes). This being said, a few recent
studies have compared genotypes separately. For instance,
Cornish et al. [22] have shown, in normal boys, an asso-
ciation between the 10/10 repeat allele genotype and
poorer mean scores on measures of selective attention and
response inhibition compared to a group of 9/10 carriers.
Joober et al. [23], using a 2-week prospective within sub-
ject crossover design have shown that children with
ADHD and carriers of the 9/9 genotype displayed a signif-
icantly weaker response to methylphenidate than carries
of the 9/10 genotype or carriers of the 10/10 genotype.
Further, a recent study [24] demonstrated that individuals
with ADHD and carriers of the 9/10 genotype tended to
fair worse than carriers of the 10/10 genotype on a large
set of variables including behavioral problems in child-
hood and adolescence, mother-teen relations at adoles-
cence, and class rankings in high school. However, no
significant differences between genotype groups were
found in Wisconsin Card Sorting Test performance. The
majority of findings in this study essentially supports the
view that young carriers of the 9/10 genotype tend to fair
worse than their 10/10 counterparts from a psychopatho-
logical perspective. While this work appears to contradict
above-mentioned studies demonstrating a disadvantage
for carriers of the 10/10 genotype, it is noteworthy that it's
the first study, to the best of our knowledge, to separately
look at DAT1 gene genotype in relation to behavior in
children with ADHD.
Overall, these patterns of results are consistent with a high
degree of heterogeneity in genetic effects and with the
view that current candidate genes are only indirectly
responsible for ADHD as they may instead be associated
with specific clinical variants and/or behavioral dimen-
sions of ADHD yet to be precisely identified. If this is the
case, selecting candidate genes on the basis of their poten-
tial implication in modulating intermediate phenotypes
(or endophenotypes) relevant to ADHD could improve
the robustness of genetic results. While endophenotypes
can exist at a number of levels, most studies to date have
focused on the neuropsychological level. One such path-
way with considerable empirical support implicates dys-
regulation of executive function processes (defined as the
neurocognitive processes that maintain an appropriate
problem-solving set to attain a future goal [25,26]). Factor
analyses of batteries of measures of executive function
have revealed the four following factors: 1) response inhi-
bition and execution, 2) working memory and updating,
3) set-shifting and task-switching, and 4) interference
control [26-30]. Although most mental tasks involve
almost every component of executive functioning to some
degree, some tasks tap relatively highly into specific fac-
tors.
While traditionally, executive function tasks have been
believed to rely mostly on the prefrontal cortex, the
involvement of the basal ganglia is now being recognized
[31,32]. For instance, it has been shown that fronto-stri-
atal pathway disconnection disrupts normal performance
on classical cognitive frontal tasks in rats [33] and that theBMC Psychiatry 2008, 8:45 http://www.biomedcentral.com/1471-244X/8/45
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executive dysfunction frequently observed in Parkinson's
disease is associated with altered pallidal-frontal process-
ing [34]. In keeping with this, one of the most replicated
morphological alterations in brains of children with
ADHD is small caudate and pallidum volumes [35].
Finding an association between executive function dysreg-
ulation and ADHD together with demonstration that
dopamine neurotransmission is critical for normal execu-
tive functioning would highlight the plausibility of execu-
tive function as an endophenotype in ADHD. From a
genetic standpoint, the DAT1 gene is known to be prefer-
entially expressed in the basal ganglia and has been
reported to influence caudate volume [36] and aspects of
executive functioning in normal subjects [22]. Further-
more and in keeping with the above, the dopamine trans-
porter has been argued to play a critical role in regulating
cortical signal-to-noise ratio during working memory via
a cortico-striato-thalamo-cortical pathway [37]. As
reviewed by Doyle et al[2], family, twin, and adoption
studies all suggest that EFs may index the familial/genetic
liability to ADHD. Given the data discussed above, DAT1
gene is a compelling candidate gene to examine in rela-
tion to both EF performance and ADHD.
The present study examined executive function perform-
ance in children with ADHD in relation to the Variable
Number of Tandem Repeats (VNTR) located in the 3'
untranslated (UTR) region of the DAT1 gene in order to
further characterize the association between genotype and
behavior in children with ADHD. It is hypothesized that




Children were sequentially recruited from the Disruptive
Behavior Disorders Program and the Children Outpatient
Clinics of the Douglas Hospital. They were referred to
these specialized care facilities by school teachers, com-
munity social workers and pediatricians.
To be included in this study, children were required to be
between 6 and 12 years of age and meet DSM-IV diagnosis
criteria for ADHD [38]. Diagnosis was based on a struc-
tured clinical interview of parents using the fourth edition
of the diagnostic interview schedule for children-parental
report (DISC-IV) [39], school reports, teachers' reports,
and clinical observation of the subject. In the majority of
cases, mothers were the primary informants for the collec-
tion of clinical information. The Child Behavioral Check-
list [40], a scale that assesses several behavioral domains
was completed by parents for each child. Children having
a history of mental retardation, with an IQ ≤ 70 as meas-
ured by the Wechsler Intelligence Scale for Children-third
edition (WISC-III) [41], a history of Tourette syndrome,
pervasive developmental disorder, psychosis, bipolar dis-
order or any medical condition or impairment that would
interfere with the ability of the child to complete the
study, were excluded. All diagnostic and baseline evalua-
tions were conducted at the Douglas Hospital.
Psychometric assessment
In order to capture the gist of the four factors of executive
functioning reported above (ie 1- response inhibition and
execution (includes planning), 2- working memory and
updating, 3- set-shifting and task-switching, and 4- inter-
ference control), our neuropsychological test battery com-
prised the Wisconsin Card Sorting Test (WCST) [42], the
Self Ordered Pointing Task (SOPT) [43], the Tower of
London (TOL), which is a variant on the Tower of Hanoi
task [44], and the WISC-III from which a Freedom from
Distractibility Index (FFDI) was extracted.
The WCST, the SOPT, and the TOL were administered by
trained research personnel as described in Taerk et al. [45].
For both tests, all children were assessed while not having
taken medication for at least one week. Both research per-
sonnel and subjects were blinded to the genotype status of
the subjects.
Furthermore, the WISC-III was administered by a trained
psychologist to all children not having had it adminis-
tered in the previous year at school. Where the WISC-III
had been administered in the previous year, records of the
evaluation were made available by the school authorities.
In all cases where records were complete, the Freedom
from Distractibility Index (FFDI) was derived from the
Arithmetic and Digit Span subtest scores. 17% of children
(n = 16) with the 9/10 genotype and 14% of children (n
= 18) with the 10/10 genotype were tested at school.
In the WCST, the child is asked to sort cards according to
three different criteria (color, number, or shape of the
symbols present on the cards). Feedback on whether the
child achieves a correct or incorrect match is given after
each trial. The matching criterion changes after ten con-
secutive correct matches and the child has to identify the
new matching criterion using the feedback (correct/incor-
rect) provided to him. While the WCST is a task where one
has to hold active information in working memory in
order to identify the matching criterion, it arguably taps
mostly into response inhibition capacity and into set-
shifting and task switching ability. Evidence for the high
reliability and validity of the WCST for various normal
and clinical populations has been reported in many stud-
ies [42]. While the WCST perseverative errors score has fre-
quently been examined in previous work pertaining to
ADHD [46], non-perseverative errors, total errors,BMC Psychiatry 2008, 8:45 http://www.biomedcentral.com/1471-244X/8/45
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number of trials to complete the first category, as well as
number of categories completed were also examined here.
In the SOPT, series of matrices of 6, 8, 10 and 12 images
are presented to the child. The child is asked to chose, by
pointing, one different image on each page. Errors occur
when the child points to images that he pointed to in pre-
vious presentations of the set of images. Each set is pre-
sented to the child three times. While performing the
SOPT, the demand on keeping information active in
working memory is very high. SOPT scores have been
shown to highly correlate with measures of working mem-
ory, strategy utilization and planning (ie response inhibi-
tion and execution), but not with measures of interference
control [47]. Test-retest reliability for the SOPT total errors
score has been shown to be high while stability of other
SOPT indices, including perseverative errors, has been
shown to be rather poor [47]. As children with ADHD
have been reported to have a poorer performance on the
SOPT total errors score than normal controls [48,49], this
index has been examined here.
In the TOL, the child is presented with colored beads with
a hole in them. These beads are placed on three pegs in a
given initial pattern. The child is asked to move the beads,
one by one, in order to match a target pattern. Beads can
only be moved from peg to peg ie they cannot be kept in
one's hand. Importantly, subjects are told to plan ahead
and try to match the target pattern with the least possible
number of moves. The TOL has twelve items of increasing
difficulty. The TOL taps relatively highly into working
memory as well as into strategy utilization and planning
[50]. The standard scores for each of the 12 items were
examined.
Numerous factor analyses of the WISC-III have revealed a
Freedom from Distractibility Index (FFDI) constituted by
the Arithmetic and Digit Span subtests [41]. Performance
on the FFDI is very likely highly influenced by deficits in
interference control and working memory and has been
found to be relatively low for children with ADHD [41].
While in the Arithmetic task, children are asked to solve
arithmetic problems, in the Digit Span subtest of the
WISC-III, children are required to repeat verbatim or in
reverse order, strings of digits recited at the rate of one per
second. The length of the strings is gradually increased.
The test is ended when the child is no longer able to cor-
rectly repeat the strings.
The research protocol was approved by the Research Eth-
ics Board of the Douglas Hospital (Montreal, Quebec).
Parents were explained the study and provided written
consent. Children were explained the study and gave their
assent to participate.
Molecular genetics
Blood samples were collected from affected children and
their parents in order to extract DNA for the purpose of
genetic analyses. The VNTR polymorphism in the SLC6A3
gene was genotyped using a PCR-based method as previ-
ously described [51]. The PCR was performed in a 15 μl
total reaction volume containing 1× PCR buffer, 200 uM
dNTPs, 100 ng of primers (5'-TGTGGTGTAGGGAACG-
GCCTGAG-3', 5'-CTTCCTGGAGGTCACGGCTCAAGG-
3'), 1 Unit of Taq DNA polymerase and 100 ng of genomic
DNA. PCR products were electrophoresed on agarose-TAE
gel along with 1 kb and 100 bp DNA ladders, visualized
under UV-light and coded according to the length of the
PCR product. Genotypes were called by two independent
and experienced technicians who were blind to all the
clinical data. No discordance in any of the readings was
noted.
Statistical analyses
The VNTR polymorphism has two main alleles: 9- and 10-
repeat alleles. Three very rare alleles (3, 7, 8 and 11-
repeat) were also identified in 13 subjects (four with the
3/10 genotype, one with the 7/10 genotype, one with the
8/10 genotype, one with the 9/11 genotype, and six with
the 10/11 genotype). Because of the very small sample
sizes of these latter genotype groups and because only 21
carriers of the 9/9 genotype were detected, we limited our
analyses to the groups of children with the 9/10 or 10/10
genotypes. The total sample size of subjects having been
genotyped for the DAT1 gene was 251. Of these, 96 had
the 9/10 genotype and 127 had the 10/10 genotype.
To test for the effect of genotype on SOPT performance,
we implemented a general linear model repeated meas-
ures analysis with genotype (2 modalities: 9/10 and 10/10
genotypes) as the between subject factor and the 4 SOPT
difficulty level error scores as the within-subject repeated
measures. A similar procedure was implemented for the
12 difficulty level scores of the TOL. An analysis of vari-
ance was implemented for the WCST and WISC-III scores.
Age was used as a covariate except when test scores were
already age-standardized (eg WISC-III subtests).
The mean of the absolute values of the correlations
between scores on the different outcome variables (WCST,
SOPT, TOL, and WISC-III performances) was modest to
moderate (mean r = 0.357). Between different tests (eg
WCST and WISC subtests), the absolute value of the cor-
relations ranged between a low of 0.042 and a high of
0.379. However, between the different indices of perform-
ance on a given test (eg comparing WCST Total errors and
WCST Perseverative errors), correlations ranged between
0.495 and 0.874. High correlations between performance
values of a given test are expected in cases when perform-
ance on one index is in part derived from performance onBMC Psychiatry 2008, 8:45 http://www.biomedcentral.com/1471-244X/8/45
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another index. Taking these correlations into account
[52], a Bonferroni correction for multiple comparisons
produced a p < 0.011 level of significance as the appropri-
ate cutoff necessary to achieve an overall p < 0.05 alpha
level.
Results
The 10- and 9-repeat allele frequencies were 72% and
28% respectively for the complete sample (ie this calcula-
tion includes subjects with the 9/9 genotype). The geno-
type distribution did not differ from the Hardy-Weinberg
equilibrium (χ2 = 0.043, df = 1, p = 0.84). Gender, ethnic
group, age, average household income, and severity of
behavioral problems as assessed by the CBCL (total, atten-
tion, internalizing and externalizing scores, and other
behavioral dimensions) were not significantly different
between the three genotype groups. Further, no significant
differences between genotype groups were found in IQ, in
diagnostic subtype of ADHD (inattentive, hyperactive/
impulsive and combined) or in the number of ADHD
items as assessed by the DISC-IV. In keeping with most
studies on ADHD, the sample was characterized by a high
prevalence of comorbidity including oppositional defiant
disorder and conduct disorder. However, there were no
significant differences in comorbid disorders between the
genotype groups (see Table 1).
The main finding of this study is a significant genotype
effect on TOL (F = 6.902, p = 0.009) and FFDI perform-
ances (F = 7.125, p = 0.008) as well as a strong trend on
SOPT error scores (F = 4,996 p = 0.026) and Digit Span
performance (F = 6.28, p = 0.023). Children with the 9/10
genotype had poorer performance on all four measures
compared to children with the 10/10 genotype (see Table
2). Scatter plots were examined and these results could
not be explained by the presence of outliers in any of the
groups (scatter plots not shown). No effect of genotype on
WCST measures of performance was detected.
Discussion
The most important finding of this study is the presence
of a significant effect of the SLC6A3 3'UTR VNTR genotype
on measures of executive function performance in chil-
dren with ADHD. Indeed, with the exception of the
WCST, it was observed that carriers of the 10/10 DAT1
gene genotype had a better performance on various tasks
of executive function than carriers of the 9/10 genotype.
While differences in results between WCST and the other
tests are probably due to multiple complex reasons, it
could be tentatively hypothesized that these are due to the
fact that the TOL, the SOPT, and the FFDI subtests all exert
rather high demands on working memory while the
WCST taps mostly on the set-shifting and task-switching
factor. Indeed, although the WCST does tap into working
memory, its demands on it are relatively low as the child
has to keep in mind a maximum of only two out of three
possible parameters at a time (ie color, shape, or number).
In contrast, the SOPT, TOL, and FFDI subtests all exert a
Table 1: Demographic and clinical characteristics of sample partitioned by DAT1 genotype
9/10 genotype 10/10 genotype Statistics and p values
n = 96 n = 127 Total n = 223
Age (yrs) 8.8 ± 1.8 9.2 ± 1.9 F = 2.78, p = .10
Proportion of males 80.2% (n = 77) 79% (n = 100) χ2 = 0.072, p = .79
Proportion of Caucasians 87.5% (n = 84) 82.7% (n = 105) χ2 = 0.98, p = .32
WISC-III FSIQ 96.7 ± 14.6 99.2 ± 14.4 F = 1.61, p = .21
CBCL total 70 ± 8.1 69.2 ± 9.3 F = 0.41, p = .35
CBCL Attention problems 70.7 ± 9.5 70.8 ± 10.2 F = 0.009, p = .92
CBCL externalisation 70.4 ± 9.4 69.1 ± 10.2 F = 0.65, p = .42
CBCL internalisation 63.7 ± 9.6 64.1 ± 11.4 F = 0.063, p = .80
Proportion with I/H/C ADHD subtype as 
assessed by the treating psychiatrist
18% (n = 17)/6% (n = 6)/74% (n = 71)
2 missing data points
27% (n = 34)/4% (n = 5)/65% (n = 82)
6 missing data points
χ2 = 3.21, p = .20
DISC-IV Inattentive 6.9 ± 2.2 7.2 ± 2.0 F = 0.51, p = .48
DISC-IV Hyperactive/Impulsive 6.3 ± 2.4 5.6 ± 2.5 F = 3.56, p = .061
with CD/without CD 32% (n = 30)/68% (n = 64)
2 missing data points
24% (n = 30)/76% (n = 94)
3 missing data points
χ2 = 1.6, p = .21
with ODD/without ODD 40% (n = 38)/60% (n = 56)
2 missing data points
41% (n = 52)/59% (n = 74)
1 missing data point
χ2 = 0.016, p = .90
Never/previously medicated 52% (n = 46)/48% (n = 43)
7 missing data points
52% (n = 60)/48% (n = 56)
11 missing data points
χ2 < 0.001, p = .99
Values are percentages or means ± their respective Standard Deviations (SD). Demographic and clinical characteristics were compared between 
the two groups using the appropriate statistic. WISC = Wechsler Intelligence Scale for Children, 3rd edition; CBCL = Child Behavioural Checklist; 
I/H/C = Inattentive/Hyperactive/Combined; DISC = Diagnostic Interview Schedule for Children, 4th edition; ODD = Oppositional Defiant Disorder; 
CD = Conduct Disorder; Percentages are rounded to the nearest unit. Note that in the DSM-IV, a diagnosis of CD supersedes a diagnosis of ODD. 
However, in order to make the table as informative as possible, this criterion was relaxed. Age was used as a covariate for all F statistics.BMC Psychiatry 2008, 8:45 http://www.biomedcentral.com/1471-244X/8/45
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very high demand on working memory whether directly
(SOPT and Digit Span FFDI subtest) or through mental
manipulations (which is one of the elements of working
memory) that have to be made while the child keeps bead
positions (TOL) or numbers (Arithmetic FFDI subtest) in
active memory. Further work will be needed to confirm
this tentative hypothesis.
While Barkley et al. (see introduction) [24] found mostly
psychopathological differences between the ADHD geno-
type groups, we evidenced a difference in executive func-
tion performance. This being said, in the only task that
overlaps between our study and theirs (ie WCST), no dif-
ference was found between groups. The other two cogni-
tive tasks that Barkley et al. administered and that may be
construed as measures of executive functioning were a
Continuous Performance Task and the Matching Familiar
Figures Test. None of these two tasks yielded a significant
genotype main effect. The fact that these two tests also
exert rather low demands on working memory may fur-
ther be viewed as supporting the above-mentioned work-
ing memory hypothesis.
As stated in the introduction and in apparent contradic-
tion with the current findings, Cornish et al. [22] and Loo
et al[17] have reported a relatively poor performance for
carriers of the 10/10 DAT1 genotype. However, Cornish et
al. conducted their work on a sample of community con-
trols and not on ADHD children while Loo et al. have
compared, in ADHD children, those with the 10/10 DAT1
genotype to a compound group where children with the
9/9 or 9/10 genotypes were pooled together [17]. In a
more recent work, Mill et al reported that IQ is lower for
those with a combination of putative genetic risk in DRD4
(7-repeat allele) and in the dopamine transporter (10/10
genotype) genes [18]. The combination of genotypes in
two separate loci and the use of two different genetic mod-
els in each of these loci preclude us from comparing our
results with this latter study.
Table 2: Comparison of neuropsychological test performance scores for each genotype group
9/10 genotype 10/10 genotype F statistic and p value
Wisconsin Card Sorting Test
Perseverative errors raw score 45 ± 22.5 40.7 ± 19.6 F = 1.29; p = 0.26
Non perseverative errors raw score 20.4 ± 12.6 19.1 ± 12.6 F = 0.11; p = 0.74
Total errors raw score 24.7 ± 15.4 22.4 ± 14.2 F = 0.63; p = 0.43
Trials to complete first category 23.9 ± 22.2 21.9 ± 18.5 F = 0.32; p = 0.57
Number of categories completed 4.1 ± 1.7 4.6 ± 1.5 F = 3.17; p = 0.076
WISC-III
Arithmetic 8.5 ± 3.0 9.4 ± 2.6 F = 3.51; p = 0.063
Digit span 7.6 ± 2.3 8.6 ± 2.3 F = 6.28; p = 0.013 *
FFDI 8.0 ± 2.3 9.0 ± 2.0 F = 7.13; p = 0.008 **
SOPT (4 levels of difficulty)
Level 1 number of errors 2.3 ± 1.6 1.9 ± 1.4
Level 2 number of errors 3.7 ± 2.1 3.0 ± 2.0
Level 3 number of errors 4.6 ± 2.6 3.7 ± 2.3
Level 4 number of errors 5.9 ± 3.6 5.0 ± 3.0
Repeated measures statistic for the SOPT F = 5.00; p = 0.026 *
TOL (12 levels of difficulty)
Level 1 score 8.2 ± 0.9 8.3 ± 0.9
Level 2 score 8.0 ± 1.5 8.3 ± 1.1
Level 3 score 7.6 ± 1.3 7.7 ± 1.1
Level 4 score 6.1 ± 2.6 6.8 ± 1.9
Level 5 score 6.5 ± 1.6 6.8 ± 1.4
Level 6 score 4.3 ± 3.0 4.8 ± 2.7
Level 7 score 4.5 ± 2.9 4.7 ± 3.0
Level 8 score 5.2 ± 2.7 5.2 ± 2.6
Level 9 score 6.3 ± 1.8 6.4 ± 1.7
Level 10 score 2.8 ± 2.8 3.0 ± 2.8
Level 11 score 4.0 ± 2.9 4.8 ± 2.4
Level 12 score 4.4 ± 2.7 4.8 ± 2.5
Repeated measures statistic for the TOL F = 6.90; p = 0.009 **
Values are mean ± SD. Statistical analyses for the SOPT and TOL were implemented using a repeated measures design. For this reason, only an 
overall F statistic is available for each of these two tests.
* → Statistical trend (0.011 < p value < 0.05).
** → Statistically significant (p value < 0.011).BMC Psychiatry 2008, 8:45 http://www.biomedcentral.com/1471-244X/8/45
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As the10-repeat allele has frequently been reported as
being a risk allele for ADHD, it may appear surprising that
those with the 10/10 genotype are not the ones with the
worst performance here. However, whether the 10-repeat
allele is or not a risk allele for ADHD is not necessarily, by
itself, very informative about its potential association with
a specific endophenotype 4(e.g. executive functioning) for
a subset of subjects with ADHD as a given.
While the current study has strengths, including a
restricted age range and the assessment of executive func-
tion using multiple indices while children were not taking
psychostimulant medication, its results should be inter-
preted with important limitations kept in mind. First, it is
noteworthy that some children were tested on the WISC-
III by different examiners prior to the initiation of the
study. However, if this had an impact on results, it is
expected to have manifested itself as statistical noise, mak-
ing results less likely to appear as significant. Second, the
study sample was mainly comprised of children with the
combined type of ADHD and not enough subjects had the
inattentive or hyperactive/impulsive subtypes in both
genotype groups, precluding us from analyzing the rela-
tion between DAT1 gene genotype and executive function
in each ADHD subtype. Further investigation in larger
groups would allow analysis of the aggregation of differ-
ent clinical aspects stratified by genotype. Third, the poly-
morphism that we studied in this sample is located in the
3'-untranslated region of the SLC6A3 gene and thus does
not change the structure of the DAT1 protein. Nonethe-
less, it has been suggested that it may affect the level of
expression of the DAT1 gene, resulting in variable
dopamine transporter phenotypes. While this may be the
case, the issue still remains controversial. Indeed, it has
been reported that DAT binding availability is signifi-
cantly lower for subjects who are homozygous for the
SLC6A3 VNTR 10-repeat allele compared to carriers of at
least one 9-repeat allele [53] while the opposite associa-
tion [54] was reported in another study and yet no associ-
ation [55] was found in a third.
Conclusion
In conclusion, results from this study show that the DAT1
gene genotype can be a marker of performance of execu-
tive functioning (perhaps mostly working memory) in
children with ADHD with those having the 9/10 genotype
generally exhibiting a relatively poorer performance than
those with the 10/10 genotype. As such, and assuming
that an endophenotype has a greater potential to target
one of the many pathophysiological deficits that in com-
bination may lead to a disorder, present results support
the view that it may be possible to characterize with a cer-
tain degree of refinement the associations between geno-
type and semiology. In the wake of frequent false positive
findings in behavioral genetics, replication of the current
findings is warranted before firm conclusions can be
drawn.
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